Skip to main content
SpringerLink
Log in

Grenzbereiche der Dosierung von Mesalazin

  • Conference paper
Chronisch entzündliche Darmerkrankungen

Part of the book series: Gastroenterologie Update ((GASTROUPDATE,volume 2001))

  • 54 Accesses

Zusammenfassung

In den vergangenen Dekaden konnten Fortschritte bei der medikamentösen Behandlung der chronisch entzündlichen Darmerkrankungen (CED) erreicht werden.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Ardizzone S, Porro GB (1998) A practical guide to the management of distal ulcerative colitis. Drugs 55: 519–542

    Article  PubMed  CAS  Google Scholar 

  • Azad Khan AK, Piris J, Truelove SC (1977) An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 2:892–895

    Google Scholar 

  • Camma C, Giunta M, Rosselli M, Cottone M (1997) Mesalamine in the maintainance treatment of Crohn’s disease: a meta-analysis adjusted for confounding variables. Gastroenterology 113:1465–1473

    Article  PubMed  CAS  Google Scholar 

  • Campieri M, Lanfranchi GA, Bertoni F et al. (1984) A double-blind clinical trial to compare the effects of 4-aminosalicylic acid to 5-aminosalicylic acid in topical treatment of ulcerative colitis. Digestion 29:204–208

    Article  PubMed  CAS  Google Scholar 

  • Caprilli R, Andreoli A, Capruso L et al. (1994) Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of post-operative recurrence of Crohn’s disease. Aliment Pharmacol Ther 8:35–43

    Article  PubMed  CAS  Google Scholar 

  • Christensen LA (1992) Release profiles and local/systemic availabilities of five oral 5- ASA-containing preparations. In: Rasmussen SN (ed) Pentasa in ulcerative colitis and Crohn’s disease. Symposium proceedings, Helsingor, Denmark 1991. Adis International, Chester

    Google Scholar 

  • Colombel J-F, Lémann M, Cassagnou M et al. (1999) A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn’s disease. Am J Gastroenterol 94: 674–678

    Article  PubMed  CAS  Google Scholar 

  • De Franchis R, Vecchi M, Carpinelli 1, Meucci G, Torgana G (1993) Comparison of the efficacy and safety of sulfasalazine and mesalazine in the maintenance of treatment of ulcerative colitis: a meta-analysis. Eur J Gastroenterol Hepatol 5:505–510

    Google Scholar 

  • Ewe K, Herfarth C, Malchow H, Jesdinsky HJ (1989) Post-operative recurrence of Crohn’s disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicenter trial. Digestion 42:224–232

    Article  PubMed  CAS  Google Scholar 

  • Feuerle GE, Theuer D, Velasco S, Barry BA, Wordehoff D, Sommer A et al. (1989) Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomized double-blind trial. Gut 30:1354–1361

    Article  Google Scholar 

  • Fockens P, Mulder CJJ, Tytgat GNJ, Blok P, Ferweda J, and the Dutch Pentasa Study Group (1995) Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Eur J Gastroenterol Hepatol 7:1025–1030

    Article  PubMed  CAS  Google Scholar 

  • Frieri G, Pimpo MT, Andreoli A et al. (1999) Prevention of post-operative recurrence of Crohn’s disease requires adequate mucosal concentration of mesalazine. Aliment Pharmacol Ther 13: 577–582

    Article  PubMed  CAS  Google Scholar 

  • Frieri G, Pimpo MT, Palumbo G, Tonelli F, Annese V et al. of the GISC (2000) Anastomotic configuration and mucosal 5-aminosalicylic acid (5-asa) concentrations in patients with Crohn’s disease: a GISC study. Am J Gastroenterol 95(6):1486–1490

    Article  PubMed  CAS  Google Scholar 

  • Gandolfo J, Farthing F, Powers G et al. (1987) 4-aminosalicylic acid retention enemas in treatment of distal colitis. Dig Dis Sci 32(7): 700–704

    Article  PubMed  CAS  Google Scholar 

  • Ginsberg AL, Beck LS, McIntosh TM, Nochomovitz LE (1988) Treatment of left-sided ulcerative colitis with 4-aminosalicylic acid enemas: a double-blind, placebo-controlled trial. Ann Intern Med 108:195–199

    PubMed  CAS  Google Scholar 

  • Hanauer S, Schwartz J, Robinson M, Roufail W, Arora S, Cello J, Safdi M, and the Pentasa Study Group (1993) Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Am J Gastroenterol 88(8): 1188–1197

    PubMed  CAS  Google Scholar 

  • Hanauer SB (1989) 5-ASA enema therapy. Neth J Med 35: S11–S20

    PubMed  Google Scholar 

  • Hanauer SB (1996) Inflammatory bowel disease. New Engl J Med 334: 841–848

    Article  PubMed  CAS  Google Scholar 

  • Hanauer SB, Schwartz J, Roufail W, Robinson M, Cello J, Safdi M et al. (1989) Doseranging study of oral mesalamine capsule (PENTASA) for active ulcerative colitis. Gastroenterology (Abstract) 96:A195

    Google Scholar 

  • Hetzel DJ, Shearman DJC, Bochner F, Imhoff DM, Gibson GE, Fitch RJ et al. (1986) Azodisalicylate (olsalazine) in the treatment of active ulcerative colitis. A placebo-controlled clinical trial and assessment of drug disposition. J Gastroent Hepatol 1: 257–266

    Article  Google Scholar 

  • Jarnerot G (1994) New salicylates as maintenance treatment in ulcerative colitis. Gut 35:1155–1158

    Article  PubMed  CAS  Google Scholar 

  • Klotz U (2000) The role of aminosalicylates at the beginning of the new millenium in the treatment of chronic inflammatory bowel disease. Eur J Clin Pharmacol 56: 353–362

    Article  PubMed  CAS  Google Scholar 

  • Lochs H, Mayer M, Fleig WE et al. (2000) Prophylaxis of postoperative relapse in Crohn’s disease with mesalamine. Gastroenterology 118: 264–273

    Article  PubMed  CAS  Google Scholar 

  • Mahida YR, Yewell DP (1990) Slow-release 5-amino-salicylic acid (Pentasa) for the treatment of active Crohn’s disease. Digestion 45: 88–92

    Article  PubMed  CAS  Google Scholar 

  • Marshall JK, Irvine EJ (1995a) Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut 40: 775–781

    Article  Google Scholar 

  • Marshall JK, Irvine EJ (1995b) Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis. Aliment Pharmacol Ther 9: 293–300

    Article  CAS  Google Scholar 

  • Messori A, Brignola C, Trallori G et al. (1994) Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn’s disease: a meta-analysis. Am J Gastroenterol 89:692–698

    PubMed  CAS  Google Scholar 

  • Messori A, Rampazzo R (1993) Meta-analysis on the maintainance of remission in Crohn’s disease. J Clin Gastroenterol 17:178–180

    Article  PubMed  CAS  Google Scholar 

  • Mulder CJJ, van den Hazel SJ (1998) Drug therapy: dose-response relationship of oral mesalazine in inflammatory bowel disease. Mediators of Inflammation 7:135–136

    Article  PubMed  CAS  Google Scholar 

  • Munakata _ et al. (1995) _ J Gastroenterol 30 (Suppl VIII): 108–111

    PubMed  CAS  Google Scholar 

  • Powell-Tuck J, Parkins RA (1984) Controlled comparison of enemas containing 1 g and 2 g 5-Aminosalicylic acid in patients with ulcerative proctosigmoiditis. Gut 25 (Abstract):A11423

    Google Scholar 

  • Prakash A, Markham A (1999) Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn’s disease. Drugs 57: 383–408

    Article  PubMed  CAS  Google Scholar 

  • Rasmussen SN, Lauritsen K, Tage-Jensen U (1987) 5-Aminosalicylic acid in the treatment of Crohn’s disease. A 16-week double-blind, placebo-controlled, multicentre study with Pentasa. Scand J Gastroenterol 22: 877–883

    Article  PubMed  CAS  Google Scholar 

  • Riley SA (1998) What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis? Gut 42:761–763

    Article  PubMed  CAS  Google Scholar 

  • Robinson M, Girnick G, Balant L, Das K, Turkin D (1988) Olsalazine in the treatment of mild to moderate ulcerative colitis. Gastroenterology (Abstract) 84: A381

    Google Scholar 

  • Safdi M, DeMicco M, Sninsky C, Banks P, Wruble L, Deren J, Koval G et al. (1997) A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 92(10): 1867–1871

    PubMed  CAS  Google Scholar 

  • Salomon P, Kornbluth A, Aisenberg J, Janowitz HD (1992) How effective are current drugs for Crohn’s disease? A meta-analysis. J Clin Gastroenterol 14:211–215

    Article  PubMed  Google Scholar 

  • Schroeder KW, Tremaine WJ, Ilstrup DM (1987) Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 317:1625–1629

    Article  PubMed  CAS  Google Scholar 

  • Selby WS, Bennett MK, Jewell DP (1984) Topical treatment of distal ulcerative colitis with 4-aminosalicylic acid enemas. Digestion 29:231

    Article  PubMed  CAS  Google Scholar 

  • Singleton J (1994) Second trial of mesalamine therapy in the treatment of active Crohn’s disease. Gastroenterology 107: 632–633

    PubMed  CAS  Google Scholar 

  • Singleton JW, Hanauer SB, Gitnick GL et al. (1993) Mesalamine capsules for the treatment of active Crohn’s disease: results of a 16-week trial. Gastroenterology 104: 1293–1301

    PubMed  CAS  Google Scholar 

  • Sninsky CA, Cort DH, Shanaban F, Powers BJ, Sessions JT, Pruitt RE et al. (1991) Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. Ann Intern Med 115:350–355

    PubMed  CAS  Google Scholar 

  • Steinhart AH, Hemphill D, Greenberg GR (1994) Sulfasalazine and mesalazine for the maintainance therapy of Crohn’s disease: a meta-analysis. Am J Gastroenterol 89: 2116–2214

    PubMed  CAS  Google Scholar 

  • Sutherland LR (1999) Aminosalicylates in the treatment of ulcerative colitis and Crohn’s disease. In: Rutgeerts P, Colombel J-F, Hanauer SB, Schölmerich J, Tytgat GMH, van Gossum A (eds) Advances in inflammatory bowel diseases. Kluwer Academic Press, Dordrecht, pp 201–209

    Google Scholar 

  • Sutherland LR (2000) Mesalamine for the prevention of postoperative recurrence: is nearly there the same as being there? Gastroenterology 118: 436–438

    Article  PubMed  CAS  Google Scholar 

  • Sutherland LR, Robinson M, Onstad G, Peppercorn M, Greenberger N, Goodman M et al. (1990) A double-blind, placebo-controlled, multi-centre study of the efficacy and safety of 5-aminosalicylic acid tablets in the treatment of ulcerative colitis. Can J Gastroenterol 4: 463–467

    Google Scholar 

  • Sutherland LR, Roth DE, Beck PL (1997) Alternatives to sulfasalazine: a meta-analysis of 5-ASA in the treatment of ulcerative colitis. Inflamm Bowel Dis 3: 65–78

    Article  Google Scholar 

  • Sutherland LR, Shaffer EA (1993) Sulfasalazine revisited: a meta-analysis of 5-amino-salicylic acid in the treatment of ulcerative colitis. Ann Int Med 118: 540–549

    PubMed  CAS  Google Scholar 

  • Svartz N (1942) Salazopyrin, a new sulfanilamide preparation. Acta Medica Scandinavia 110:557–590

    Google Scholar 

  • Tremain WJ, Schroeder KW, Harrison JM, Zinsmeister AR (1994) A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preperation, Asacol, in the treatment of symptomatic Crohn’s colitis and ileocolitis. J Clin Gastoenterol 19:278–282

    Article  Google Scholar 

  • Tromm A, Griga T, May B, (1999) Oral mesalazine for the treatment of Crohn’s disease: clinical efficacy with respect to pharmacokinetic properties. Hepatogastroenterology 46:3124–3135

    PubMed  CAS  Google Scholar 

  • Wilding IR, Kenyon CJ, Hooper G (2000) Gastrointestinal spread of oral prolonged-release mesalazine microgranules (Pentasa®) dosed as either tablets or sachet. Aliment Pharmacol Ther 14:163–169

    Article  PubMed  CAS  Google Scholar 

  • Wright JP, Jewell DP, Modigliani R, Malchow H for the International Organisation for the Study of Inflammatory Bowel Disease (IOIBD) (1995) A randomized, double-blind, placebo-controlled trial of olsalazine for active Crohn’s disease. Inflamm Bowel Dis 1:214–216

    Google Scholar 

  • Zinberg J, Molinas S, Das KM (1990) Double-blind placebo-controlled study of olsalazine in the treatment of ulcerative colitis. Am J Gastroenterol 85:562–566

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. M. Gök
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. Oelschlegel
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Medizinische Klinik II, Universitätsklinikum Frankfurt am Main, Theodor-Stern-Kai 7, 60590, Frankfurt/Main, Deutschland

    Jürgen Stein

  2. Virchow-Kliniken, Universitätsklinikum der Humboldt-Universität, Augustenburger Platz 1, 13353, Berlin, Deutschland

    Axel Dignass

  3. Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Universitätsklinikum Charité, Augustenburger Platz 1, 13353, Berlin, Deutschland

    Axel Dignass

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Gök, M., Oelschlegel, L. (2001). Grenzbereiche der Dosierung von Mesalazin. In: Stein, J., Dignass, A. (eds) Chronisch entzündliche Darmerkrankungen. Gastroenterologie Update, vol 2001. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59505-9_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-59505-9_5

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-42509-0

  • Online ISBN: 978-3-642-59505-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation